What Has Driven the Growth of the Chronic Kidney Disease Market in Recent Years?
The chronic kidney disease market has seen considerable growth due to a variety of factors.
•There has been a solid expansion in the chronic kidney disease market size in the past few years. The market is anticipated to rise from $70.65 billion in 2024 to $75.09 billion in 2025, marking a compound annual growth rate (CAGR) of 6.3%.
This growth during the historic period is primarily due to factors such as the hypertension and diabetes outbreak, increased aging population, poor health habits, unequal access to healthcare, and advancements in medical technology.
What is the Market Size Forecast for the Chronic Kidney Disease Market?
The chronic kidney disease market is expected to maintain its strong growth trajectory in upcoming years.
• There is an anticipated robust expansion in the chronic kidney disease market in the upcoming years, with estimated growth to $95.85 billion by the year 2029, projecting a compound annual growth rate (CAGR) of 6.3%.
Several factors can explain the escalated growth during the forecast period - a concentrated focus on healthcare policies, advancements in precision medicine, the surge in obesity rates, an increase in chronic diseases, and better access to healthcare facilities. Some significant trends to look out for during this forecast period include early detection drives, the rise of telemedicine and remote health monitoring, patient empowerment strategies, initiatives emphasizing community-based care, and the integration of nutritional therapy.
What Factors Are Driving Growth In The Chronic Kidney Disease Market?
The escalating occurrence of kidney disease is likely to boost the progression of the chronic kidney disease market in the coming future. Kidney diseases encompass a range of disorders impacting kidney functionality and its structure. Treatment for kidney disease aims to regulate patients' blood pressure, minimize protein loss to prevent the advancement of kidney dysfunction, manage signs and forestall outcomes. For example, data from the Centers for Disease Control and Prevention, a public health institution based in the US, revealed that around 15%, tantamount to 37 million people in the US, battled kidney disease in July 2022. Hence, the escalating occurrence of kidney disease is a key factor propelling the growth of the chronic kidney disease market.
What Are The Main Segments Of The Global Chronic Kidney Disease Market?
The chronic kidney disease market covered in this report is segmented –
1) By Diagnosis: Blood Test, Urine Test, Imaging Test, Kidney Biopsy
2) By Treatment: Drugs, Dialysis, Kidney Transplant, ACE Inhibitors, Blood Test, Other Treatments
3) By Route of Administration: Oral, Intravenous, Subcutaneous
4) By End-User: Hospital And Clinics, Ambulatory Surgery Centers (ASCs), Dialysis Centers, Other End-Users
Subsegments:
1) By Blood Test: Serum Creatinine Test, Glomerular Filtration Rate (GFR) Test, Blood Urea Nitrogen (BUN) Test, Electrolyte Tests
2) By Urine Test: Urinalysis, 24-hour Urine Collection, Urine Protein Test, Urine Albumin-To-Creatinine Ratio (ACR)
3) By Imaging Test: Ultrasound, CT Scan, MRI, X-ray
4) By Kidney Biopsy: Percutaneous Kidney Biopsy, Open Kidney Biopsy, Laparoscopic Kidney Biopsy
Pre-Book The Chronic Kidney Disease Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Chronic Kidney Disease Market?
Innovations in product development are emerging as a crucial trend in the chronic kidney disease market. Firms in this market are creating novel products to maintain their market presence. For example, Bayer, a biotech and pharmaceutical company based in Germany, introduced a pioneering medicine, Kerendia (finerenone), in August 2022 to curb the advancement of chronic kidney disease in people with diabetes. This medication has a unique non-steroidal, selective mineralocorticoid receptor antagonist character that sets it apart from existing treatments. Its function is to inhibit the overactivation of the mineralocorticoid receptor (MR), a factor that enhances CKD progression and cardiovascular damage.
Who Are the Key Players in the Chronic Kidney Disease Market?
Major companies operating in the chronic kidney disease market include:
• Pfizer Inc
• Johnson and Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Bayer AG
• Novartis International AG
• Sanofi SA
• Bristol-Myers Squibb Company
• Abbott laboratories Inc.
• GlaxoSmithKline PLC
• Takeda Pharmaceuticals Ltd.
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.
• Novo Nordisk AS
• Siemens Healthineers AG
• AstraZeneca Pharmaceuticals LP
• Teva Pharmaceutical Industries Ltd.
• Beckman Coulter Inc.
• Kissei Pharmaceutical Co. Ltd.
• Akebia Therapeutics Inc.
• Mission Therapeutics Ltd.
• Tricida Inc.
• Regulus Therapeutics Inc.
• Goldfinch Bio Co
• Alio Inc.
• Monogram Health
• Strive Health
• Maze Therapeutics
• ProKidney Corp
What Is The Most Dominant Region In The Chronic Kidney Disease Market?
North America was the largest region in the chronic kidney disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
